E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
in pediatric patients with relapsed or refractory leukemia |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the maximum tolerated dose (MTD) for two age groups (≥3 months to ≤2 years: >2years to <18 years) of pediatric patients with AML or MLL based on the rate of dose-limiting toxicity (DLT) of midostaurin administered orally in dose ranges studied in adults. |
|
E.2.2 | Secondary objectives of the trial |
• To characterize the safety and tolerability of midostaurin, including acute and chronic toxicities • To characterize the peak and trough levels of single and repeated doses of midostaurin and its metabolite(s), • To determine the response rates, time to relapse and overall survival of patients treated with midostaurin. • To determine the presence of activating mutations or WT-overexpression of the FLT3 gene in MLL-rearranged ALL and AML samples • To correlate baseline levels of FLT3 phosphorylation with FLT3 expression levels and clinical outcome in MLL patients • To correlate baseline levels of FLT3 phosphorylation with activating FLT3 mutations and clinical outcome in AML patients • To evaluate changes in FLT3 phosphorylation following treatment with midostaurin, and correlate changes with clinical outcome • To evaluate changes in FLT3 phosphorylation following treatment with midostaurin, and correlate with pharmacokinetic data |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients must have a documented diagnosis of one of the following leukemias: • MLL-rearranged ALL, refractory to standard induction treatment or in first or subsequent relapse • FLT3-mutated AML refractory to standard induction (after failure of at least 2 different induction chemotherapy regimens) or refractory to reinduction at 1st relapse (after failure of the first re-induction course), or in second or greater relapse 2. Patients must be less than 18 years of age and ≥3 months of age. 3. Patients must have a Lansky/Karnofsky performance status ≥ 60. 4. Patients must have the following laboratory values reflecting appropriate organ function: • AST and ALT ≤ 5x Upper Limit of Normal (ULN), • Serum Bilirubin ≤ 1.5 x ULN, • Serum Creatinine ≤ 2 x ULN. 5. Patients must have an expected survival of greater than 8 weeks.
|
|
E.4 | Principal exclusion criteria |
1. Patients with symptomatic leukemic CNS involvement. 2. Patients with isolated extramedullary leukemia. 3. Patients must have recovered from prior cytotoxic chemotherapy, and a minimum wash-out time of previous chemotherapy of 72 hours should be taken into account. 4. Patients who had prior allogeneic, syngeneic or autologous bone marrow or stem cell transplant less than 2 months from Day 1 5. Patients who have received any investigational agent within 30 days or 5 half lives, whichever is greater, prior to Day 1. An investigational agent is an agent with no approved medical uses in adults or pediatrics. 6. Patients who have had prior treatment with a FLT3 inhibiting drug or investigational agent. 7. Use of CYP3A4/5 enzyme inducing or inhibiting drugs or herbal supplements while on study treatment 8. The use of corticosteroids while on study drug 9. Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin or bone marrow biopsy), within 14 days of Day 1. 10. Patients with any other known disease concurrent severe and/or uncontrolled medical condition (e.g. cardiovascular disease including congestive heart failure or active uncontrolled infection) which could compromise participation in the study. 11. Patients with an abnormal chest X-ray and/or any pulmonary infiltrate including those suspected to be of infectious origin. In particular, patients with resolution of clinical symptoms of pulmonary infection but with residual pulmonary infiltrates on chest x-ray are not eligible until pulmonary infiltrates have completely resolved. 12. Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin, including active graft-versus-host disease of the liver or the gut. 13. Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis. 14. Patients with a left ventricular shortening fraction < 27% as determined by MUGA scan or echocardiogram 15. Patients with abnormal ECG including: • QTcF ≥ 450 ms, PR ≥200 msec, QRS complex ≥110 msec, at screening • Any cardiac conduction abnormality • Any morphologic abnormality • Any ST/T wave abnormality • Any atrial or ventricular arrhythmia 16. Female patients who are pregnant or breast feeding or patients of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial by both sexes, if applicable. 17. Males of reproductive potential unwilling to comply with contraceptive requirements 18. Patients/parents unwilling or unable to comply with the protocol |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Safety: Occurrence of dose-limiting toxicities (DLTs) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
After discontinuation of study treatment, patients will be follewed up for survival untille death. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |